Selectively substituted quinoline compounds

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO RE47193
SERIAL NO

15668887

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • EISAI R & D MANAGEMENT CO., LTD.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Carlson, J Eric Merrimack, US 3 1
Davis, Heather Haverhill, US 23 584
Endo, Atsushi Andover, US 122 1600
Hansen, Hans Somerville, US 49 2006
Hawkins, Lynn Concord, US 20 194
Ishizaka, Sally Weston, US 12 98
Mackey, Matthew Melrose, US 12 98
Ogawa, Chikako Basel, CH 7 46
Schiller, Shawn Haverhill, US 28 241

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 8, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 8, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00